Key result
Baseline data from 18,240 patients with schizophrenia randomized to ziprasidone or olanzapine showed high cardiovascular risk, including 46.5% current smokers and 28.9% with obesity.
Why the study?
Does ziprasidone compared to olanzapine increase the risk of nonsuicide mortality in patients with schizophrenia?
Population
18,240 patients with schizophrenia in naturalistic practice, mean age 41.6 years, 55.1% male, from 18…
Comparison
Ziprasidone vs Olanzapine
Design
RCT, Randomly assigned to either ziprasidone or olanzapine, Open-label
Follow-up
1 year
Authors
Loading...
High CV risk in schizophrenia warrants monitoring; leaves open whether ziprasidone or olanzapine modifies outcomes.
RCT (n=18,240)
Open-label
Randomized
Yes
Does ziprasidone compared to olanzapine increase the risk of nonsuicide mortality in patients with schizophrenia?
The ZODIAC study is a large, pragmatic randomized trial designed to evaluate the cardiovascular safety of ziprasidone versus olanzapine in patients with schizophrenia, a population with a high prevalence of undertreated cardiovascular risk factors.
Storm et al. (2008) conducted an RCT in Schizophrenia (n=18,240). Ziprasidone vs. Olanzapine was evaluated on Rate of nonsuicide mortality in the year after initial recommendation for therapy. Baseline data from 18,240 patients with schizophrenia randomized to ziprasidone or olanzapine showed high cardiovascular risk, including 46.5% current smokers and 28.9% with obesity.